Relmada Therapeutics (RLMD) Tops Q2 EPS by 24c

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.59), $0.24 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Varonis Systems (VRNS) call put ratio 4.4 calls to 1 put with a focus on July 35, 40 and 45 calls as share price up 6.4%